A PI3K gene expression signature predicts for recurrence in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy (SBRT).

INTRODUCTION Increasingly, early-stage non-small cell lung cancer (NSCLC) is treated with stereotactic body radiation therapy (SBRT). Although treatment is generally effective, a small subset of tumors will recur because of radioresistance. Preclinical studies suggested PI3K-AKT-mTOR activation mediates radioresistance. This study sought to validate this finding in tumor samples from patients who underwent SBRT for NSCLC. METHODS Patients with T1-3N0 NSCLC treated with SBRT at our institution were included. Total RNA of formalin-fixed paraffin-embedded tumor biopsy specimens (pretherapy) was isolated and analyzed using the Clariom D assay. Risk scores from a PI3K activity signature and four published NSCLC signatures were generated and dichotomized by the median. Kaplan-Meier curves and Cox regressions were used to analyze their association with recurrence and overall survival (OS). The PI3K signature was also tested in a data set of resected NSCLC for additional validation. RESULTS A total of 92 patients were included, with a median follow-up of 18.3 months for living patients. There was no association of any of the four published gene expression signatures with recurrence or OS. However, high PI3K risk score was associated with higher local recurrence (hazard ratio [HR], 11.72; 95% CI, 1.40-98.0; p = .023) and worse disease-free survival (DFS) (HR, 3.98; 95% CI, 1.57-10.09; p = .0035), but not OS (p = .49), regional recurrence (p = .15), or distant recurrence (p = .85). In the resected NSCLC data set (n = 361), high PI3K risk score was associated with decreased OS (log-rank p = .013) but not DFS (p = 0.54). CONCLUSIONS This study validates that higher PI3K activity, measured by gene expression, is associated with local recurrence and worse DFS in early-stage NSCLC patients treated with SBRT. This may be useful in prognostication and/or tailoring treatment, and merits further validation.

[1]  E. Taioli,et al.  Association of Stage Shift and Population Mortality Among Patients With Non–Small Cell Lung Cancer , 2021, JAMA network open.

[2]  W. Curran,et al.  Surgical Outcomes for Early-Stage Non-Small Cell Lung Cancer at Facilities with Stereotactic Body Radiation Therapy Programs. , 2021, Chest.

[3]  A. Kishan,et al.  A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. , 2020, European urology.

[4]  J. Galvin,et al.  Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial , 2018, JAMA oncology.

[5]  W. Curran,et al.  Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy , 2018, Cancer.

[6]  Joe Y. Chang,et al.  Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer , 2018, JAMA network open.

[7]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[8]  C. Simone,et al.  Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer. , 2018, Lung cancer.

[9]  E. Yorke,et al.  PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT) , 2017, Clinical and translational radiation oncology.

[10]  C. Robinson,et al.  Treatment of stage I non–small cell lung cancer: What's trending? , 2017, The Journal of thoracic and cardiovascular surgery.

[11]  Lewis C. Cantley,et al.  The PI3K Pathway in Human Disease , 2017, Cell.

[12]  P. Xia,et al.  A Histologic Basis for the Efficacy of SBRT to the lung , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  R. Deberardinis,et al.  NRF2 regulates serine biosynthesis in non-small cell lung cancer , 2015, Nature Genetics.

[14]  Ash A. Alizadeh,et al.  Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. , 2015, Journal of the National Cancer Institute.

[15]  M. Hellmich,et al.  PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies , 2014, Oncotarget.

[16]  Ralph R. Weichselbaum,et al.  DNA Repair Pathway Gene Expression Score Correlates with Repair Proficiency and Tumor Sensitivity to Chemotherapy , 2014, Science Translational Medicine.

[17]  Kehu Yang,et al.  The expression of hypoxia-inducible factor-1α and its clinical significance in lung cancer: a systematic review and meta-analysis. , 2013, Swiss medical weekly.

[18]  R. Deng,et al.  PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation , 2011, Oncogene.

[19]  Igor Jurisica,et al.  Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. Oyen,et al.  The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[22]  Silke von Ahlfen,et al.  Determinants of RNA Quality from FFPE Samples , 2007, PloS one.

[23]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[24]  P. Catalano,et al.  Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer. , 2015, Clinical lung cancer.

[25]  Zhongxing Liao,et al.  Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  S. Hilsenbeck,et al.  Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer , 2010, Breast Cancer Research.